Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Department of Endocrinology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Front Immunol. 2024 Oct 4;15:1448818. doi: 10.3389/fimmu.2024.1448818. eCollection 2024.
Neutrophils have long been consistently adjudged to hold a dominant position in acute inflammation, which once led people to undervalue their role in chronic malignancy. It is now acknowledged that neutrophils also infiltrate into the tumor microenvironment in substantial quantities and form a highly abundant immune population within the tumor, known as tumor-associated neutrophils (TANs). There has been a surge of interest in researching the eminent heterogeneity and plasticity of TANs in recent years, and scholars increasingly cotton on to the multifaceted functions of TANs so that strenuous endeavors have been devoted to enunciating their potential as therapeutic targets. Yet it remains much left to translate TAN-targeted immunotherapies into clinical practice. Therefore, there is great significance to comprehensively appraise the research status, focal point, and evolution trend of TAN by using bibliometric analysis.
Publications related to TAN research from 2000 to 2024 are extracted from the Web of Science Core Collection. Bibliometric analysis and visualization were performed by tools encompassing Microsoft Excel, VOSviewer, CiteSpace, R-bibliometrix, and so on.
The bibliometric analysis included a total of 788 publications authored by 5291 scholars affiliated with 1000 institutions across 58 countries/regions, with relevant articles published in 324 journals. Despite China's maximum quantity of publications and top 10 institutions, the United States is the leading country with the most high-quality publications and is also the global cooperation center. FRONTIERS IN IMMUNOLOGY published the most papers, whereas CANCER RESEARCH is the highest co-cited journal. Israeli professor Fridlender, Zvi G. is the founder, pioneer, and cultivator with the highest citation counts and H-index in the TAN area. Our analysis prefigures the future trajectories: TAN heterogeneity, neutrophil extracellular trap, the crosstalk between TANs and immunocytes, and immunotherapy will likely be the focus of future research.
A comprehensive bibliometric and visual analysis is first performed to map the current landscape and intellectual structure of TAN, which proffers fresh perspectives for further research. The accurate identification of distinct TAN subpopulations and the precise targeting of key pro-tumor/anti-tumor subpopulations hold immense potential to develop into a TAN-targeted immunotherapy.
中性粒细胞在急性炎症中一直被认为占据主导地位，这使得人们低估了它们在慢性恶性肿瘤中的作用。现在人们已经认识到，中性粒细胞也大量浸润到肿瘤微环境中，并在肿瘤内形成一种高度丰富的免疫群体，称为肿瘤相关中性粒细胞（TAN）。近年来，人们对 TAN 的显著异质性和可塑性的研究兴趣激增，学者们越来越意识到 TAN 的多方面功能，因此投入了大量精力来阐明它们作为治疗靶点的潜力。然而，将 TAN 靶向免疫疗法转化为临床实践仍有许多工作要做。因此，通过文献计量分析全面评估 TAN 的研究现状、焦点和演变趋势具有重要意义。
从 Web of Science 核心合集提取 2000 年至 2024 年与 TAN 研究相关的出版物。使用 Microsoft Excel、VOSviewer、CiteSpace、R-bibliometrix 等工具进行文献计量分析和可视化。
文献计量分析共纳入 788 篇文献，作者来自 58 个国家/地区的 1000 个机构的 5291 位学者，相关文章发表在 324 种期刊上。尽管中国发表的论文数量最多，前 10 名机构数量最多，但美国是发文质量最高的国家，也是全球合作中心。FRONTIERS IN IMMUNOLOGY 发表的论文最多，而 CANCER RESEARCH 是被引频次最高的期刊。以色列教授 Fridlender，Zvi G. 是 TAN 领域被引频次和 H 指数最高的创始人、先驱和培育者。我们的分析预示了未来的轨迹：TAN 异质性、中性粒细胞胞外陷阱、TAN 与免疫细胞的串扰以及免疫疗法可能成为未来研究的焦点。
首次对 TAN 进行全面的文献计量和可视化分析，为进一步研究提供了新的视角。准确识别不同的 TAN 亚群，并精确靶向关键的促肿瘤/抗肿瘤亚群，有可能发展成为 TAN 靶向免疫疗法。
